Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Research Offers New Hope for HIV/AIDS Patients with Cancer

Published: Thursday, August 23, 2012
Last Updated: Wednesday, August 22, 2012
Bookmark and Share
Proposed treatment for herpes virus that causes Kaposi's sarcoma receives translational research funding.

A proposed new treatment to help HIV/AIDS patients suffering from Kaposi’s sarcoma, the most common form of cancer in people with HIV, is now one step closer to becoming a reality.

Charles S. Craik, PhD, a professor in the UCSF School of Pharmacy, has received new support to develop his latest research on the herpes virus that causes Kaposi’s sarcoma through a $100,000 T1 Translational Catalyst Award offered through UCSF’s Clinical and Translational Science Institute (CTSI).

Craik, who works in the Department of Pharmaceutical Chemistry, is known for leading the team that identified HIV protease inhibitors in the late 1980s.

An especially promising aspect of Craik’s research is its potential to also lead to a new treatment for the cytomegalovirus (CMV), a related herpes virus that can lead to pneumonia and gastrointestinal, retinal and neurological diseases in infants and in transplant recipients and other immunocompromised individuals.

A successful new CMV treatment would be “huge,” said Craik, who is also affiliated with the California Institute for Quantitative Biosciences (QB3) located at UCSF's Mission Bay campus. “Currently, there are very few treatments for CMV. If you don’t respond to them or can’t tolerate them, there’s nothing else to offer you.”

The immediate target of Craik’s prospective medication is Kaposi’s sarcoma herpes virus (KSHV) protease, an enzyme that cleaves proteins, Craik explains. Viruses, including HIV, use proteases to reproduce and to promote infection.

The T1 Catalyst Award is offered twice a year, and is designed to help move promising early-stage research through the lengthy and complex process of translating ideas into therapies to benefit patients.

CTSI’s T1 Catalyst Award will allow Craik to develop molecules to block the KSVH protease and test them in the lab using a tissue culture approach.

“If the new compound blocks the virus without killing the surrounding cells, it will have great potential for working in animal models,” Craik said. “We’re already making promising progress there.”

Craik’s project was chosen as the final winner by a panel of business and industry experts who reviewed proposals from nine finalists.

Other winners included Tejal Desai, PhD, a professor in the School of Pharmacy; Ari Green, MD, an assistant professor in the School of Medicine; and Jay Stewart, MD, an associate professor in the School of Medicine.

Awards Process Benefits From Expert Advice
The T1 Catalyst Award process is different from other awards because of the support that finalists receive from industry experts, Craik said. “In the finalist stage, we were paired with two fantastic consultants who worked with us to improve the project and helped us address key issues related to clinical and product development that will increase the likelihood of our work ultimately reaching patients.”

Craik’s consultants were Nancy Shulman, MD, a clinical infectious disease specialist at Genentech; and Brian Metcalf, PhD, a medicinal chemist and chief scientific officer of Global Blood Therapeutics.

“Both helped me refine my ideas about the unmet need we were addressing, and especially what was truly novel about our approach,” Craik said.

Another award finalist, Peder Larson, PhD, assistant professor of radiology and biomedical imaging at UCSF’s School of Medicine, noted that he benefited from the award process even though his project was not selected as a winner.

Larson’s proposal involved a new contrast agent that would potentially indicate in a Magnetic Resonance Imaging (MRI) scan whether a prostate cancer tumor is actively growing or not. “The agent would tell you on a functional level what the tumor tissues are doing - giving you an indication of the nature of the tumor and how aggressive it is,” he said.

He worked to refine his proposal with the advice of project consultants June Lee, MD, FACCP, director of the Early Translational Research program at CTSI; Greg Naeve, PhD, head of strategic research partnerships at Pfizer; and Teresa Burgess, PhD, adjunct associate professor of Molecular, Cellular and Developmental Biology at UC Santa Barbara.

With their help, Larson realized that he had not been asking the tough questions about the details of where the technique would be applied clinically: At what stage of prostate cancer treatment would someone get this procedure? How would it translate into a clinically and commercially viable new technique?

Larson admits that as an academic, he found the experience somewhat outside of his comfort zone.

Ultimately, he said, because he is trying to develop translational technologies, he now understands the importance of working with people in industry who know how that process works and with clinical partners who will be the end users of new technology.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Thursday, August 20, 2015
How Early Childhood Vaccination Reduces Leukemia Risk
Chronic infections push ‘pre-leukemia’ cells, common in newborns, into malignancy.
Thursday, May 21, 2015
Human Cancer Prognosis Is Related to Newly Identified Immune Cell
A rare population of tumor-associated “good” cells slows cancer.
Monday, October 20, 2014
Type 1 Diabetes Drug Proves Effective in Clinical Trial
Drug developed by UCSF researcher shows promise for blocking advance of disease in earliest stages.
Thursday, August 08, 2013
HIV Testing Increased and Infection Reduced in Africa with Community Intervention
Free mobile HIV testing and counseling, same-day results and post-test support reduces HIV infections by 14 percent.
Thursday, March 07, 2013
Stem Cell Survival Strategy Is Key to Blood and Immune System Health
Stem cells of the aging bone marrow recycle their own molecules to survive and keep replenishing the blood and immune systems as the body ages.
Monday, February 18, 2013
Multiple Sclerosis ‘Immune Exchange’ Between Brain and Blood is Uncovered
UCSF finding of movement by disease-causing B cells gives hope for new treatments and diagnostics.
Thursday, November 22, 2012
NIH Awards $15 Million Grant to UCSF-CFAR
UCSF-CFAR awarded more than $15 million over the next five years to continue UCSF-Gladstone AIDS research.
Thursday, October 18, 2012
New Standards to Improve Diagnosis of Sjögren’s Syndrome
UCSF-led team of international researchers develop criteria to identify autoimmune disease.
Tuesday, August 14, 2012
Researchers Identify a Potential New HIV Vaccine/Therapy Target
Investigators first determine levels of Th17 cells in the gut of sixteen rhesus macaques and then infected them with SIV.
Monday, June 04, 2012
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos